ASCO GU 2022 Olaparib plus abiraterone as first-line therapy for patients with metastatic castration-resist... Read more
ASCO GU 2022 Promising antitumour activity with neoadjuvant enfortumab vedotin in cisplatin-ineligible musc... Read more